For years, Kasia Lipska, MD, MHS, associate professor of medicine (endocrinology) at Yale School of Medicine (YSM), has been ...
Weights, aerobics, and … Wegovy? Some in the fitness industry are moving to dispense the popular GLP-1 medications to club ...
As the treatment of obesity in the 21st century takes a monumental turn, the need for quality care is more pressing than ever: Tips for starting a new obesity-focused practice.
Researchers at Karolinska Institute have potentially discovered a novel method to combat obesity and associated conditions by ...
The North Carolina state treasurer is taking on drugmakers Novo Nordisk and Eli Lilly in an attempt to lower drug costs for ...
Roche Joins Race for Obesity Drugs With $2.7 Billion Carmot Deal Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of ...
Ozempic and weight-loss drugs raise hopes for obesity, but complexities exist. The Ozempic buzz plays into ideas of fat stigma and fatphobia. The Ozempic doesn't work same for everyone. Drugs ...
LONDON — Following a nine-month investigation, European regulators said Friday they have found no evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions. The ...
People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don’t shed a lot of weight on the medication ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Twinamatsiko and Ranganathan are experts in health law and ...
It is understandable for U.S. investors to be focused on the largest technology companies that have driven such strong performance for the S&P 500 over the past decade. But learning about ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BrainStorm Cell Therapeutics said the FDA agreed to a ...